Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Non-adhesive Liquid Embolic Materials market size was valued at approximately USD 410 million in 2025. The market is projected to reach USD 670 million by 2032, exhibiting a compound annual growth rate (CAGR) of approximately 7.5% during the forecast period from 2025 to 2032. This growth is primarily driven by the rising global prevalence of cerebrovascular diseases and oncology, which are major clinical application areas for these materials.
Non-adhesive liquid embolic materials are injectable agents used in minimally invasive endovascular procedures. Their unique property is the ability to transform from a liquid to a cohesive solid or gel state within a blood vessel, occluding it permanently without adhering to the vessel walls. This non-adhesive characteristic is crucial because it minimizes the risk of catheter entrapment and reduces inflammatory response and damage to adjacent healthy tissues. These materials play a critical role in treating brain arteriovenous malformations (AVMs), hypervascular tumors, and aneurysms where precise, targeted embolization is required.
The markets expansion is fueled by the growing adoption of neurointerventional radiology and advancements in microcatheter technology. Furthermore, the increasing preference for minimally invasive surgical techniques over traditional open surgery is a significant driver, as these procedures offer shorter hospital stays and improved patient recovery. Key players, including Medtronic plc, Stryker Corporation (owner of MicroVention), and Johnson & Johnson (CERENOVUS), maintain a strong market presence through continuous product innovation. For instance, in recent years, companies have worked on developing next-generation formulations with enhanced radiopacity for better visibility under fluoroscopy and improved control over the polymerization rate, directly addressing procedural efficacy and safety.
Increasing Prevalence of Neurovascular Disorders
The rising global incidence of conditions such as brain arteriovenous malformations (AVMs), cerebral aneurysms, and hypervascular tumors is a primary driver. These conditions often require minimally invasive endovascular embolization, where non-adhesive liquid embolics are frequently the agent of choice due to their ability to penetrate complex vasculature. The aging population, a key risk factor for many neurovascular diseases, sustains procedural demand.
Advancements in Embolic Agent Technology
Continuous innovation in material science has led to the development of second and third-generation non-adhesive liquid embolics with improved properties. These include enhanced radiopacity for better visualization under fluoroscopy, more predictable precipitation and polymerization times, and reduced viscosity for deeper vessel penetration. Such technological refinements improve procedural success rates and safety profiles, encouraging wider clinical adoption.
The shift towards minimally invasive surgical techniques across global healthcare systems has significantly bolstered the market for liquid embolization, as it offers reduced patient trauma, shorter hospital stays, and lower overall costs compared to traditional open surgeries.
Furthermore, the expansion of interventional radiology and neuroradiology as specialized fields, coupled with growing physician training and expertise in these techniques, is a fundamental driver underpinning market growth.
MARKET CHALLENGES
Technical Complexity and Procedural Risks
The precise delivery of non-adhesive liquid embolics requires significant skill and experience. Risks include unintended embolization of normal vessels, catheter retention, and material reflux, which can lead to serious complications. Variations in blood flow and vascular anatomy add to the procedural complexity, creating a steep learning curve and limiting widespread use to specialized centers.
Other Challenges
Stringent Regulatory Pathways and High Costs
Achieving regulatory approval for new embolic agents is a lengthy and costly process due to the high-risk nature of the intended use. This barrier to entry limits the number of new market competitors. Additionally, the high cost of these materials and the associated specialized delivery systems can constrain adoption in cost-sensitive healthcare markets and limit reimbursement coverage.
Competition from Alternative Embolic Agents
Non-adhesive liquid embolics face competition from adhesive glues, coils, particles, and sclerosants. The choice of agent is highly procedure- and patient-specific. In some indications, such as certain aneurysms, detachable coils may be preferred, while particle embolics dominate in tumor embolization, creating a fragmented competitive landscape.
High Cost of Treatment and Economic Constraints
The overall cost of an embolization procedure utilizing non-adhesive liquid agents is substantial, encompassing the price of the embolic material itself, specialized microcatheters, and imaging equipment. This economic burden acts as a major restraint, particularly in developing regions and within healthcare systems operating under strict budget caps, potentially limiting patient access to this advanced treatment modality.
Limited Long-Term Clinical Data for Newer Agents
While newer generations of non-adhesive liquid embolics show promising short-term results, the availability of robust, long-term clinical data on durability, recanalization rates, and chronic tissue reaction is still evolving. This evidence gap can make some physicians cautious about adopting newer products over more established, familiar treatment options with longer clinical track records.
Expansion into New Clinical Indications
There is significant potential for market growth through the exploration and validation of non-adhesive liquid embolics for new applications beyond neurovascular disorders. Research and clinical trials are investigating their use in peripheral vascular malformations, trauma, and visceral pathologies such as gastrointestinal bleeding or renal aneurysms, which could substantially expand the addressable patient population.
Growth in Emerging Geographic Markets
Emerging economies in Asia-Pacific, Latin America, and the Middle East present a major growth frontier. Improving healthcare infrastructure, rising medical tourism, increasing investment in advanced interventional suites, and a growing awareness of minimally invasive treatment options are creating new, high-volume markets for these specialized medical devices.
Development of Next-Generation Smart Embolic Systems
The convergence of embolic materials with biotechnology and imaging presents a frontier opportunity. Research is focused on developing "smart" liquid embolics that could deliver therapeutic agents (e.g., chemotherapeutics for tumors), possess enhanced biodegradability for temporary occlusion, or include integrated imaging markers, creating a new class of combination products with higher value.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Direct Injection formulations represent the leading segment, primarily due to their procedural efficiency and widespread physician familiarity in complex vascular interventions. These materials offer superior controllability and rapid solidification upon contact with blood, which is critical for precise vessel occlusion in delicate anatomical regions like the neurovasculature. The segment's dominance is further reinforced by continuous technological refinements that enhance radiopacity and delivery precision, directly addressing the core clinical need for predictable embolization. Special Injection types, while also advancing, cater to more specific and technically demanding procedural requirements. |
| By Application |
|
Neurovascular Interventional Treatment is the unequivocal leading application, driven by the high clinical value of these materials in treating cerebral arteriovenous malformations and aneurysms. The non-adhesive property is paramount here, minimizing the risk of catheter entrapment and vessel wall injury during delicate brain procedures, which significantly improves patient safety profiles. The growing adoption of minimally invasive endovascular techniques over open surgery for complex neurovascular conditions continues to propel this segment's prominence. Tumor embolization applications also show robust growth, particularly for hypervascular tumors, leveraging the material's ability to penetrate distal vasculature for more complete devascularization. |
| By End User |
|
Hospitals, particularly large tertiary care and academic medical centers, constitute the dominant end-user segment. This leadership is attributed to their consolidated infrastructure for complex interventional radiology and neurology suites, availability of multidisciplinary specialist teams, and the high volume of intricate neurovascular and oncological cases requiring these advanced materials. The capital-intensive nature of the required imaging and catheterization equipment further centralizes procedures in hospital settings. Specialty clinics are increasingly adopting these technologies for certain elective procedures, supported by the broader trend toward outpatient care for suitable patient cohorts. |
| By Material Property |
|
Radiopaque / Visible materials lead this category as real-time visualization under fluoroscopy is a non-negotiable requirement for safe and effective embolization procedures. This property allows interventionalists to accurately track the material's flow, prevent non-target embolization, and confirm complete occlusion of the target vessel, which is critical for procedural success and patient safety. Continuous innovation focuses on enhancing radiopacity without compromising the material's biocompatibility or rheological properties. The development of combination materials with tunable viscosity represents a significant frontier, offering physicians greater intraprocedural control. |
| By Procedural Approach |
|
Curative / Definitive Embolization stands as the leading segment by procedural intent, particularly in neurovascular applications where the goal is the permanent occlusion of pathological vessels like brain AVMs. The material's unique property of solidifying without adhering to vessel walls makes it exceptionally suitable for this purpose, enabling a durable, cast-like fill of the vascular nidus. The growth of this segment is closely tied to advancements in microcatheter technology and imaging, allowing for safer navigation and more precise delivery. Pre-operative embolization for surgical tumor resection also represents a significant and growing use case, leveraging these materials to reduce intraoperative bleeding. |
A Highly Specialized Market Led by Medtronic and Terumo
The non-adhesive liquid embolic materials market is characterized by a concentrated competitive structure with a few global medical device leaders holding significant revenue share. Medtronic and Terumo are established frontrunners, leveraging their extensive neurovascular portfolios and global distribution networks. These leaders compete on technological innovation, clinical data, and strategic partnerships with healthcare providers. The market's growth is driven by increasing adoption of minimally invasive neurovascular and tumor embolization procedures, where these non-adhesive materials offer crucial benefits like controlled delivery and reduced tissue adhesion compared to traditional agents. Competitive intensity is high in R&D, with a focus on developing next-generation materials with improved radiopacity, viscosity control, and biocompatibility.
Beyond the top-tier players, several companies have carved out significant niches. Companies like Balt and MicroVention (a Terumo company) are strongly positioned in specific neurointerventional segments, particularly for treating cerebral arteriovenous malformations (AVMs). Boston Scientific and CERENOVUS (Johnson & Johnson) bring substantial scale and compete across broader peripheral and neurovascular markets. The landscape also features specialized manufacturers, such as Guerbet with its expertise in contrast media, and emerging players from Asia, including Meril Life, GRAND Pharmaceutical, and Sexs Biotech, which are expanding their presence and contributing to regional market dynamics with competitive pricing and localized product development.
List of Key Non-adhesive Liquid Embolic Materials Companies ProfiledMedtronic plc
Balt Extrusion (Balton Capital Group)
MicroVention, Inc. (Terumo Group)
Meril Life Sciences Pvt. Ltd.
Boston Scientific Corporation
GRAND Pharmaceutical Group Limited
Sexs Biotech Co., Ltd.
Stryker Corporation
Cook Medical LLC
Kaneka Corporation
Shape Memory Medical Inc.
The global market for Non-adhesive Liquid Embolic Materials is projected to experience significant growth from 2025 to 2032, propelled primarily by increasing demand in neurovascular interventions. These materials, which solidify in vessels without adhering to walls, are a critical tool for treating conditions like cerebral arteriovenous malformations and aneurysms. Their non-adhesive nature minimizes trauma to surrounding healthy tissue, improving patient outcomes and quality of life. Among application segments, neurovascular interventional treatment is the dominant driver, underscoring the clinical focus on minimally invasive neurological procedures. Geographically, the United States represents the largest established market, while China is anticipated to show accelerated growth, reflecting broader healthcare advancements and access to innovative treatments in the region.
Other TrendsProduct Type Segmentation and Innovation
The market is segmented by delivery method, with the Direct Injection category holding a substantial share and expected to reach a multi-million dollar valuation by 2032. This reflects procedural preference and existing product portfolios. Concurrently, manufacturers are investing in research to enhance the performance characteristics of both direct and special injection materials, focusing on improved controllability and radiopacity. This innovation is crucial for addressing complex anatomies, such as those found in tumor embolization procedures, which is the second major application area after neurovascular.
Consolidated Competitive LandscapeThe competitive environment is characterized by the presence of established global medical device and pharmaceutical companies. In 2025, the top five players, including Medtronic, Terumo, and Boston Scientific, collectively accounted for a significant portion of global revenue. This consolidation indicates high barriers to entry driven by stringent regulatory requirements and the need for extensive clinical validation. Market participants are actively engaged in strategic activities, including product development and potential mergers, to strengthen their positions and capture growth in emerging markets. The Asia-Pacific region, beyond China, is viewed as a key area for future expansion due to its rising healthcare expenditure and growing patient base for vascular diseases.
Regional Analysis: Non-adhesive Liquid Embolic Materials MarketEurope
Europe represents a major and technologically advanced market, driven by strong national healthcare systems and a high concentration of specialized neurovascular centers. The market benefits from harmonized regulatory standards under the MDR, although cost-containment pressures influence purchasing decisions. Adoption varies, with Western European countries like Germany, France, and the UK demonstrating high procedural volumes for the treatment of cerebral AVMs and tumors. Emphasis on minimally invasive techniques and growing clinical evidence supporting the long-term efficacy of liquid embolics are key drivers. While market access can be fragmented, the region is a vital hub for clinical research and product development, contributing significantly to the evolution of embolization protocols and material science.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for non-adhesive liquid embolic materials, fueled by improving healthcare infrastructure, rising healthcare expenditure, and increasing awareness of minimally invasive treatment options. Countries like Japan, China, and Australia are at the forefront, with Japan holding a particularly strong position due to its advanced medical technology landscape and early adoption. A large patient population and a growing incidence of cerebrovascular diseases present significant opportunities. Market growth is supported by expanding training programs for interventional radiologists and neurologists, though adoption rates vary widely, with emerging economies facing challenges related to procedural costs and access to specialized centers. Strategic initiatives by global players to establish local presence are accelerating market penetration.
South America
The South American market is in a developing stage but shows promising growth potential. Market activity is concentrated in major economies such as Brazil and Argentina, where advanced medical centers in urban areas perform complex neurointerventional procedures. Growth is primarily driven by a gradual increase in the availability of specialized healthcare services and the training of local physicians in endovascular techniques. However, market expansion is tempered by economic volatility, budget constraints in public healthcare systems, and uneven access to cutting-edge medical technologies across the continent. Partnerships for medical education and efforts to improve reimbursement scenarios are crucial for fostering broader adoption of non-adhesive liquid embolic materials in the region.
Middle East & Africa
The Middle East & Africa region presents a heterogeneous market landscape. Wealthier Gulf Cooperation Council countries, with their state-of-the-art private and public hospitals, are early adopters, importing the latest technologies and attracting skilled medical professionals. In contrast, broader Africa faces significant challenges, including limited healthcare infrastructure and a scarcity of specialized interventional neuroradiology services. Overall, the market is nascent but growing, driven by medical tourism hubs in the Middle East and increasing investments in healthcare modernization in select nations. Market development is heavily dependent on medical training initiatives, geopolitical stability, and the establishment of referral centers capable of managing complex neurovascular cases requiring advanced embolization materials.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Non-adhesive Liquid Embolic Materials market was valued at USD 410 million in 2025 and is expected to reach USD 670 million by 2032.
Which key companies operate in Global Non-adhesive Liquid Embolic Materials Market?
-> Key players include Medtronic, Terumo, Balt, MicroVention (Stryker), CERENOVUS (Johnson & Johnson), Boston Scientific, and Meril Life, among others.
-> The market is projected to grow at a CAGR of approximately 7.5% during the forecast period from 2025 to 2032.
-> Key growth drivers include rising prevalence of cerebrovascular diseases and oncology, adoption of minimally invasive techniques, and advancements in microcatheter technology.
-> Neurovascular interventional treatment is a major application segment, driven by the treatment of conditions like brain arteriovenous malformations (AVMs) and aneurysms.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates